11 completed, 3 active not recruiting, 2 terminated, 1 withdrawn. 17 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 11, Active not recruiting 3, Terminated 2, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow ceritinib: new trials by email Literature Review of ceritinib trials Research Report on ceritinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC Ceritinib, Docetaxel - Non-small Cell Lung Cancer, Lung Cancer | Phase 1 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 21 | 2019-02-01 | 2026-05-15 |
| Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma Ceritinib, Trametinib - Melanoma, Unresectable Melanoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 27 | 2018-06-27 | 2026-02-27 |
| Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma Brentuximab Vedotin, Ceritinib, Laboratory Biomarker Analysis - Anaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present | Phase 1 / Phase 2 | Withdrawn | University of Washington | 2018-01-03 | 2019-10-10 | |
| Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Ceritinib, Trametinib - Non-small Cell Lung Cancer | Phase 1 | Terminated | University of California, San Francisco | 9 | 2017-09-09 | 2022-12-27 |
| Next Generation Personalized Neuroblastoma Therapy Biopsy, Next Generation Sequencing, Tumor Scans - Neuroblastoma, Cancer | Phase 1 | Terminated | Yael P Mosse | 66 | 2016-07-01 | 2026-03-10 |
| Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer Ceritinib, Everolimus, Laboratory Biomarker Analysis - ALK Positive, Locally Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 37 | 2016-06-22 | 2026-05-20 |
| A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors ceritinib, warfarin, midazolam - ALK-positive Advanced Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 33 | 2015-10-23 | 2020-12-19 |
| Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer Ceritinib (LDK378), Nivolumab - ALK-positive NSCLC | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 57 | 2015-05-27 | 2026-09-17 |
| Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. Ribociclib, Ceritinib - Non-small Cell Lung Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 27 | 2015-05-14 | 2020-12-17 |
| Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) ceritinib - Non-Small Cell Lung Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 306 | 2015-04-09 | 2022-02-09 |
| Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer Ceritinib, Cisplatin, Gemcitabine Hydrochloride - Advanced Malignant Solid Neoplasm, ALK Positive | Phase 1 | Completed | Roswell Park Cancer Institute | 38 | 2015-01-08 | 2022-07-25 |
| LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib LDK378 - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 103 | 2014-03-07 | 2019-02-20 |
| Effect of Hepatic Impairment on LDK378 Pharmacokinetics LDK378 - Normal Hepatic Function, Impaired Hepatic Function | Phase 1 | Completed | Novartis Pharmaceuticals | 36 | 2014-01-01 | 2020-12-19 |
| Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) Ceritinib - ALK-activated Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 83 | 2013-08-28 | 2020-06-09 |
| Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer LDK378, AUY922 - Anaplastic Lymphoma Kinase (ALK), Non-small Cell Lung Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 22 | 2013-06-01 | 2020-12-19 |
| Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) LDK378 - Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) | Phase 1 | Completed | Novartis Pharmaceuticals | 22 | 2012-06-01 | 2020-12-19 |
| A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase LDK378 - Tumors Characterized by Genetic Abnormalities of ALK | Phase 1 | Completed | Novartis Pharmaceuticals | 304 | 2011-01-24 | 2019-03-15 |
Carcinoma, Non-Small-Cell Lung (8) · Neoplasms (3) · Lung Neoplasms (2) · Lymphoma, Large-Cell, Anaplastic (2) · Neuroblastoma (2) · Granuloma, Plasma Cell (1) · Melanoma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Rhabdomyosarcoma (1)
Novartis Pharmaceuticals (10) · H. Lee Moffitt Cancer Center and Research Institute (2) · M.D. Anderson Cancer Center (1) · Roswell Park Cancer Institute (1) · University of California, San Francisco (1) · University of Washington (1) · Yael P Mosse (1)
United States (15) · Italy (7) · Spain (7) · Australia (5) · Canada (4) · South Korea (4) · Belgium (3) · Germany (3) · Netherlands (3) · Singapore (3) · United Kingdom (3) · France (2) · Taiwan (2) · Austria (1) · Brazil (1)
Andreas Saltos, M.D. (1) · Andrei Shustov (1) · Collin Blakely, MD, PhD (1) · George R Blumenschein (1) · John M Maris, MD (1) · Renuka Iyer (1) · Zeynep Eroglu, M.D. (1)
PMID 24670165, PMID 26020125, PMID 26337354, PMID 26973324, PMID 27565932, PMID 29518553, PMID 30697903, PMID 34780709, PMID 34890832, PMID 36545322
2014 (2), P30CA015704 (1)